Novartis showcases dermatology leadership on International Urticaria Day announcing new data to be presented at EADV 2014

New data for the IL-17A inhibitor AIN457 (secukinumab) in psoriasis and Xolair in Chronic Spontaneous Urticaria (CSU) at EADV to highlight benefit to patients' quality of life. Data continue to reinforce the landmark Phase III results of secukinumab in psoriasis and Xolair in CSU that showed consistent, fast efficacy and acceptable safety Important head-to-head trial of secukinumab versus Stelara (CLEAR), powered to evaluate superiority in clearing skin, completed patient enrolment in record time The digital press release with multimedia content can be accessed here: Basel, 1 October 2014 - Novartis announced today, on the first-ever International Urticaria Day, that 15 abstracts from the Novartis specialty dermatology portfolio, will be presented at the European Association of Dermatology and Venereology (EADV) Congress, 8-12 October, in Amsterdam, Netherlands. The abstracts include new analyses of pivotal Phase III studies for AIN457 (secukinumab) in moderate-to-severe plaque psoriasis and Xolair (omalizumab) in Chronic Spontaneous Urticaria (CSU) highlighting benefit to patients' quality of life. The new data to be presented at EADV continue to reinforce the previously presented landmark Phase III results of secukinumab in psoriasis and Xolair in CSU that showed consistent, fast efficacy in the treatment of these debilitating diseases - . In an update on ongoing Novartis dermatology trials, the Phase IIIb CLEAR study finished full enrolment of 679 moderate-to-severe plaque patients earlier than expected after recruitment started in February 2014.